Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …

Drug resistance is mainly responsible for cancer recurrence and poor prognosis. Epigenetic
regulation is a heritable change in gene expressions independent of nucleotide sequence …

Histone demethylase LSD1 plays key roles during carcinogenesis, targeting LSD1 is
becoming an emerging option for the treatment of cancers. Numerous LSD1 inhibitors have …

Patients with acute myeloid leukemia (AML) frequently relapse after chemotherapy, yet the
mechanism by which AML reemerges is not fully understood. Herein, we show that primary …

The flexibility of the epigenome has generated an enticing argument to explore its reversion
through pharmacological treatments as a strategy to ameliorate disease phenotypes. All …

Chromatin regulators play a broad role in regulating gene expression and, when gone awry,
can lead to cancer. Here, we demonstrate that ablation of the histone demethylase LSD1 in …

Small-cell lung cancer (SCLC) is a deadly tumour accounting for approximately 15% of lung
cancers and is pathologically, molecularly, biologically and clinically very different from other …

Biomarker discovery and validation are necessary for improving the prediction of clinical
outcomes and patient monitoring. Despite considerable interest in biomarker discovery and …

Epigenetic dysregulation is a common feature of most cancers, often occurring directly
through alteration of epigenetic machinery. Over the last several years, a new generation of …

Next-generation sequencing has revealed that more than 50% of human cancers harbour
mutations in enzymes that are involved in chromatin organization. Tumour cells not only are …